CAR T therapy exhibits encouraging proficiency in R/R LBCL
The first study assessing Yescarta® as second-line therapy for transplant ineligible relapsed/refractory (R/R) large B-cell lymphoma (LBCL) demonstrated durable remission rate in a Phase II trial.
Kite’s Yescarta® (axicabtagene ciloleucel) facilitated a high response rate in transplant ineligible relapsed/refractory (R/R) large B-cell lymphoma (LBCL), Phase II study results show.
Patients with R/R LBCL who had received one prior line of therapy and were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) were evaluated in the trial.
Phase II “ALYCANTE is the first study to assess axicabtagene ciloleucel as second-line therapy for transplant ineligible R/R LBCL and the results showed high response rates and durable remission in this hard-to-treat population,” stated Professor Roch Houot, Head of the Haematology Department at University Hospital of Rennes in France.
The study achieved a best objective response (OR) and complete response (CR) rates of 91.9 percent and 82.3 percent, respectively.
Complete metabolic response (CMR) of 71 percent was observed at three months versus 12 percent expected with standard of care. At six months, 59.7 percent of patients remained in CMR.
Median progression-free survival (PFS) from infusion, after a median follow-up of 12 months, was 11.8 months. Consequently, 48.8 percent of evaluated patients were alive and progression-free at 12 months.
ارسال به دوستان